Tofacitinib show efficacy in treatment of severe alopaecia
Tofacitinib has a potential to treat severe alopaecia areata (AA), alopaecia totalis and alopaecia universalis, suggests a recent study.
A common autoimmune disorder, AA has no reliably effective therapies, according to researchers.
A retrospective study was conducted to assess the safety and efficacy of the Janus kinase 1/3 inhibitor tofacitinib in a series of patients over an extended period of time. Included were individuals (aged ≥18 years; n=90) with AA with at least 40 percent scalp hair loss treated with tofacitinib.
The percent change in Severity of Alopecia Tool (SALT) score during treatment was the primary endpoint.
There was a total of 65 potential responders to therapy. These responders were defined as patients with alopaecia totalis or alopaecia universalis with duration of current episode of disease of ≤10 years, or AA. Of these, 77 percent achieved a clinical response, with 58 percent of patients achieving more than 50-percent change in SALT score over 4 to 18 months of treatment.
A higher percent change in SALT score was achieved by patients with AA compared with those with alopaecia totalis or alopaecia universalis (81.9 vs 59.0 percent).
Tofacitinib was well tolerated, and no serious adverse events were recorded.
The study was limited by the retrospective nature of the data, the relatively small number of patients and lack of a control group, according to researchers, adding that randomized controlled trials are warranted to better define tofacitinib dose response.